These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3892706)

  • 61. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study.
    Fleming RA; Capizzi RL; Rosner GL; Oliver LK; Smith SJ; Schiffer CA; Silver RT; Peterson BA; Weiss RB; Omura GA
    Cancer Chemother Pharmacol; 1995; 36(5):425-30. PubMed ID: 7634384
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia.
    Takahashi S; Okamoto SI; Shirafuji N; Ikebuchi K; Tani K; Shimane M; Matsudaira T; Irie S; Tsuruta T; Matsuishi E
    Bone Marrow Transplant; 1994 Mar; 13(3):239-45. PubMed ID: 7515298
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Detection of the resistance to Ara-C blast cells in acute myeloid leukemia using flow cytometry].
    Lacombe F; Belloc F; Dumain P; Puntous M; Cony-Makhoul P; Bernard P; Boisseau MR; Reiffers J
    Bull Cancer; 1995; 82(5):349-56. PubMed ID: 7626842
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Results of a clinical study of the preparation Lenvis in leukemias in children and adults].
    Kondrat'eva NA; Kruglova GV; Kovaleva LG; Makhonova LA; Volkova MA
    Probl Gematol Pereliv Krovi; 1981 Dec; 26(12):16-21. PubMed ID: 7036140
    [No Abstract]   [Full Text] [Related]  

  • 65. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Favourable remission rate by repeating low dose ARA-C treatment in ANLL and RAEB.
    Izumi Y; Sawada H; Okazaki T; Mochizuki T; Ishikura H; Tashima M; Yamagishi M; Uchino H
    Br J Haematol; 1985 Sep; 61(1):187-90. PubMed ID: 4052328
    [No Abstract]   [Full Text] [Related]  

  • 67. [Current procedure for glucocorticoid therapy in leukemias].
    Goncharova ND; Goncharov NP; Vorontsov VI; Lebedev VN; Lebedeva IuL
    Sov Med; 1981; (4):43-7. PubMed ID: 6945675
    [No Abstract]   [Full Text] [Related]  

  • 68. Treatment of CML blast crisis with low dose ARA-C.
    di Raimondo F; Milone G; Guglielmo P; Cacciola E; Giustolisi R
    Br J Haematol; 1985 Aug; 60(4):773-4. PubMed ID: 3861196
    [No Abstract]   [Full Text] [Related]  

  • 69. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia.
    Raza A; Maheshwari Y; Preisler HD
    Blood; 1987 Jun; 69(6):1647-53. PubMed ID: 3555651
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inhibition of proliferation of human leukaemic cell populations by deferoxamine.
    Foa P; Maiolo AT; Lombardi L; Villa L; Polli EE
    Scand J Haematol; 1986 Jan; 36(1):107-10. PubMed ID: 3485303
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cell kinetics in acute leukemia: a critical reevaluation based on new data.
    Hiddemann W; Büchner T; Andreeff M; Wörmann B; Melamed MR; Clarkson BD
    Cancer; 1982 Jul; 50(2):250-8. PubMed ID: 7083131
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Combined autoradiographic and cytophotometric study of the composition and kinetics of cell populations in chronic myeloleukemia].
    Kotel'nikov VM; Kasatkina VV; Khoroshko ND
    Gematol Transfuziol; 1983 Apr; 28(4):17-20. PubMed ID: 6574083
    [No Abstract]   [Full Text] [Related]  

  • 73. Evaluation of in vitro predictive assays for acute myelocytic leukemia.
    Preisler HD
    Blut; 1980 Nov; 41(5):393-6. PubMed ID: 6934015
    [No Abstract]   [Full Text] [Related]  

  • 74. [Patient with hypoplastic leukemia successfully treated with N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine].
    Uchida M; Tsutani H; Kagawa D; Ueda T; Domae N; Nakamura T
    Nihon Naika Gakkai Zasshi; 1985 Dec; 74(12):1709-13. PubMed ID: 3831195
    [No Abstract]   [Full Text] [Related]  

  • 75. Neutralization in vivo of Lewis antibodies. Report of two cases.
    Andorka DW; Arosemena A; Harris JL
    Am J Clin Pathol; 1974 Jul; 62(1):47-51. PubMed ID: 4525441
    [No Abstract]   [Full Text] [Related]  

  • 76. Cytarabine and leukaemia remission.
    Harris AL
    Lancet; 1978 Feb; 1(8059):333. PubMed ID: 75373
    [No Abstract]   [Full Text] [Related]  

  • 77. Multidrug resistance in acute myeloid leukemia.
    Nagourney RA
    J Natl Cancer Inst; 1991 Oct; 83(19):1418-9. PubMed ID: 1920485
    [No Abstract]   [Full Text] [Related]  

  • 78. [Histochemical investigations on acute and chronic myelocytic leukemias. Proliferation of leukemic cells].
    Müller D
    Blut; 1966 Mar; 12(6):329-39. PubMed ID: 5218397
    [No Abstract]   [Full Text] [Related]  

  • 79. In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity.
    Motta MR; Baccarani M; Rizzi S; Fanin R; Fasola G; Poluzzi C; Tura S
    Blut; 1987 May; 54(5):299-306. PubMed ID: 3567369
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bone marrow cells in the DNA-synthesis-phase in the myelodysplastic syndrome and lymphome.
    Wenthzel AM; Porwit A; Lindahl K; Widell S; Reizenstein P
    Med Oncol Tumor Pharmacother; 1992; 9(1):51-5. PubMed ID: 1341321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.